Nautilus Neurosciences and APR Applied Pharma Research s.a. Announce Extension of Patent Protection for CAMBIA™ (diclofenac potassium for oral solution) through 2026 8 September 2010
Helsinn announces the official opening of its new R&D centre of excellence in Dublin 1 September 2010
APR Applied Pharma Research s.a. of Switzerland launches its new corporate website and announces key strategic changes in its Business Model to better compete in the rapidly changing Healthcare industry 15 June 2010
MonoSol Rx Announces FDA Approval of Zuplenz Oral Soluble Film for Treatment of Nausea and Vomiting 9 June 2010
Nautilus Neurosciences Announces U.S. Launch of CAMBIA (Diclofenac Potassium for Oral Solution) for the Treatment of Migraine 8 June 2010
Linkedin